CA2074790A1 - Methods for detecting pre-clinical iddm - Google Patents

Methods for detecting pre-clinical iddm

Info

Publication number
CA2074790A1
CA2074790A1 CA 2074790 CA2074790A CA2074790A1 CA 2074790 A1 CA2074790 A1 CA 2074790A1 CA 2074790 CA2074790 CA 2074790 CA 2074790 A CA2074790 A CA 2074790A CA 2074790 A1 CA2074790 A1 CA 2074790A1
Authority
CA
Canada
Prior art keywords
bsa
antibodies
mammal
children
serum
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2074790
Other languages
English (en)
French (fr)
Inventor
H. Michael Dosch
Brian H. Robinson
Julio M. Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HSC Research and Development LP
Original Assignee
HSC Research and Development LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HSC Research and Development LP filed Critical HSC Research and Development LP
Priority to CA 2074790 priority Critical patent/CA2074790A1/en
Priority to AU46932/93A priority patent/AU4693293A/en
Priority to JP6504052A priority patent/JPH07509232A/ja
Priority to EP93917471A priority patent/EP0652898A1/de
Priority to PCT/CA1993/000304 priority patent/WO1994002507A2/en
Publication of CA2074790A1 publication Critical patent/CA2074790A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA 2074790 1992-07-28 1992-07-28 Methods for detecting pre-clinical iddm Abandoned CA2074790A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA 2074790 CA2074790A1 (en) 1992-07-28 1992-07-28 Methods for detecting pre-clinical iddm
AU46932/93A AU4693293A (en) 1992-07-28 1993-07-28 Methods for detecting pre-clinical iddm
JP6504052A JPH07509232A (ja) 1992-07-28 1993-07-28 症状発現前のｉｄｄｍの検出方法
EP93917471A EP0652898A1 (de) 1992-07-28 1993-07-28 Verfahren zur feststellung von praklinischen iddm
PCT/CA1993/000304 WO1994002507A2 (en) 1992-07-28 1993-07-28 Methods for detecting pre-clinical iddm

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA 2074790 CA2074790A1 (en) 1992-07-28 1992-07-28 Methods for detecting pre-clinical iddm

Publications (1)

Publication Number Publication Date
CA2074790A1 true CA2074790A1 (en) 1994-01-29

Family

ID=4150211

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2074790 Abandoned CA2074790A1 (en) 1992-07-28 1992-07-28 Methods for detecting pre-clinical iddm

Country Status (5)

Country Link
EP (1) EP0652898A1 (de)
JP (1) JPH07509232A (de)
AU (1) AU4693293A (de)
CA (1) CA2074790A1 (de)
WO (1) WO1994002507A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2402795A (en) * 1994-05-03 1995-11-29 Hsc Research And Development Limited Partnership Methods for controlling t lymphocyte mediated immune responses
FR2740223B1 (fr) * 1995-10-19 1997-11-14 Commissariat Energie Atomique Procede de determination d'auto-anticorps revelateurs de complications pathologiques ; dans le serum sanguin, en particulier de diabetiques

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0543945B1 (de) * 1990-08-17 1996-10-16 The University Of Florida Verfahren und komposition zum frühnachweiss und behandlung insulinabhängiger diabetes

Also Published As

Publication number Publication date
EP0652898A1 (de) 1995-05-17
JPH07509232A (ja) 1995-10-12
WO1994002507A3 (en) 1994-03-17
AU4693293A (en) 1994-02-14
WO1994002507A2 (en) 1994-02-03

Similar Documents

Publication Publication Date Title
Tzioufas et al. The clinical relevance of antibodies to ribosomal-P common epitope in two targeted systemic lupus erythematosus populations: a large cohort of consecutive patients and patients with active central nervous system disease
Pietropaolo et al. Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes
Hanson et al. Biosynthesis of granulysin, a novel cytolytic molecule
Yoshimi et al. Clinical and pathological roles of Ro/SSA autoantibody system
EISENBARTH et al. The polyglandular failure syndrome: disease inheritance, HLA type, and immune function: studies in patients and families
Lindberg et al. Islet autoantibodies in cord blood from children who developed type I (insulin-dependent) diabetes mellitus before 15 years of age
JP6861771B2 (ja) 腎疾患のためのマーカー
Lutz et al. Naturally occurring autoantibodies to exoplasmic and cryptic regions of band 3 protein, the major integral membrane protein of human red blood cells.
Sheng et al. Anti-β2-glycoprotein I autoantibodies from patients with the “antiphospholipid” syndrome bind to β2-glycoprotein I with low affinity: dimerization of β2-glycoprotein I induces a significant increase in anti-β2-glycoprotein I antibody affinity
Barker et al. Identification of T-cell epitopes on the Rhesus polypeptides in autoimmune hemolytic anemia
Miao et al. Role of autoantibodies in type 1 diabetes
Osterland et al. Inherited C2 deficiency and systemic lupus erythematosus: studies on a family
Elsayed et al. Evaluation of the allergenicity and antigenicity of bovine‐milk αs1‐casein using extensively purified synthetic peptides
Rich et al. Myelin oligodendrocyte glycoprotein‐35–55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA‐DR2‐transgenic mice
Karjalainen et al. Disease-associated anti-bovine serum albumin antibodies in type 1 (insulin-dependent) diabetes mellitus are detected by particle concentration fluoroimmunoassay, and not by enzyme linked immunoassay
Lévy-Marchal et al. Antibodies against bovine albumin and other diabetes markers in French children
ZuRAw et al. Immunoglobulin E-rheumatoid factor in the serum of patients with rheumatoid arthritis, asthma, and other diseases.
US4239743A (en) Carrier-bound immunoglobulin fission product and its use in immunologic analyses
JPH06502916A (ja) 糖尿病自己抗体の検出方法
CA2083150A1 (en) Synthetic senescent cell antigen
Flint et al. Anti–LAMP-2 Autoantibodies in ANCA-Associated Pauci-Immune Glomerulonephritis
TUčKOVÁ et al. Molecular mimicry as a possible cause of autoimmune reactions in celiac disease? Antibodies to gliadin cross-react with epitopes on enterocytes
CA2074790A1 (en) Methods for detecting pre-clinical iddm
Bahr et al. An association between Gc (vitamin D-binding protein) alleles and susceptibility to rheumatic fever.
Postoway et al. Standardization of IgG subclass antiserums for use with sensitized red cells

Legal Events

Date Code Title Description
FZDE Dead